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Background: The British Society of Gastroenterology
guidelines recommend taking at least four duodenal
biopsy specimens at the time of upper gastrointestinal
(UGI) endoscopy if coeliac disease (CD) is suspected
and it has been shown to increase the diagnostic yield
of CD. We assessed the compliance to these guidelines
within our institution. We then applied measures to
improve our compliance rate and assessed the
resulting impact on our diagnostic rate of CD.
Methods: We performed a retrospective audit of
electronic records for all patients, with no prior
diagnosis of CD, who underwent UGI endoscopy with
duodenal biopsies between August 2014 and May
2015. We implemented measures to raise awareness
among endoscopy users at our institution and carried
out a reaudit between February and May 2016.
Results: 924 patients were found to be eligible in the
first part of the study and 278 in the second part. The
proportion of patients who had ≥4 biopsy specimens
submitted increased from 21.9% to 60.8% (p<0.001).
The diagnostic rate of CD increased from 3.5% in the
audit group to 7.6% in the reaudit group (p=0.004).
A positive serology result and suspected CD as an
indication for biopsy were found to be independent
predictors of the likelihood of complying with
guidelines.
Conclusions: Our study suggests that taking <4
duodenal biopsy specimens to assess for the presence
of CD may lead to the diagnosis of CD being missed.
Simple measures can improve the local compliance
rate to current guidelines.
INTRODUCTION
Coeliac disease (CD) is a common condition
with a prevalence of at least 1% in the UK.1
CD can present with a range of symptoms
including vague and non-specific abdominal
symptoms similar to irritable bowel syn-
drome.2 With time, the proportion of
patients presenting with atypical symptoms
has also increased.3 Thus, it is important to
ensure that when CD is considered as a
potential diagnosis, patients are adequately
investigated to avoid missing the diagnosis.
The lifetime risk of malignancy, especially
intestinal lymphoma and other gastrointes-
tinal cancers, in fact, slightly increased in
CD4 with studies quoting an incidence of
lymphoma of 8%.5
Endoscopy remains the mainstay of adult
CD diagnosis. As histological changes in CD
can be patchy, several biopsies should be
taken from the bulb and more distal duode-
num at the time of endoscopy. Updated
guidelines from the British Society of
Gastroenterology (BSG) on the management
of adult CD recommend taking at least four
duodenal biopsies, including one from the
bulb, if CD is suspected.6 This is based on a
large study involving 132 352 patients without
known CD, which showed that taking ≥4
duodenal biopsy samples resulted in a doub-
ling of the diagnostic rate of CD compared
with when <4 samples were taken.7 This is
further supported by evidence from a retro-
spective study involving patients with known
CD, which showed that the sensitivity for a
diagnosis of CD increased with incremental
Summary box
▸ Mucosal changes can be patchy in coeliac
disease (CD).
▸ The British Society of Gastroenterology (BSG)
recommends taking at least four biopsy speci-
mens if CD is suspected at the time of
endoscopy.
▸ Previous studies have shown that this increases
the diagnostic rate of CD.
▸ Despite existence of clear BSG guidance, com-
pliance to this is quite poor in our unit, which
may reflect a more widespread problem.
▸ This may be due to a lack of awareness of
guidelines, or other barriers.
▸ Simple interventional measures may help to
improve compliance and potentially improve the
diagnostic rate of CD.
▸ Our results should prompt other units to audit
their practice and implement measures to
improve adherence to current recommendations,
and thus the care of patients with potential CD.
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biopsies, and the diagnosis could be confirmed in 100%
of patients when four biopsy specimens were taken.8
We carried out a study to assess our compliance to the
BSG guidelines in patients without known CD. Following
implementation of measures to improve compliance, we
also aimed to determine the influence of better compli-
ance to guidelines on our local diagnostic rate of CD.
METHODS
A list of all patients who had endoscopic duodenal biop-
sies submitted for histopathological analysis to the
Barnsley General Hospital NHS Foundation Trust (UK)
pathology laboratory over a 10-month period from
August 2014 to May 2015 was retrieved from the labora-
tory database using coding. For each set of specimens
submitted, the date of specimen collection, the clinician
performing the biopsy, and patient age and sex were
also available. Using the Integrated Clinical
Environment (ICE—the online system for pathology
reporting), we obtained information on the main indica-
tion for biopsy, the number of biopsy samples for each
specimen, histopathology report and results of IgA
anti-tTG antibody tests if performed (as this is the most
widely available serology test for CD screening locally
especially in primary care).
We presented the results of this first part of our study
at the local Endoscopy User Group meeting in
November 2015. This meeting is attended by endosco-
pists in the trust who have regular endoscopy lists and
therefore perform the majority of endoscopies in the
unit, as well as endoscopy nurses. While most of these
clinicians were present, a number did not attend. We
therefore also put up posters summarising the results of
our findings in all clinical areas within the endoscopy
unit to raise awareness of the importance of complying
with guidelines among endoscopists and to encourage
and remind them to take the appropriate number of
biopsies. We then collected data using the same
methods described above for duodenal biopsies submit-
ted for histopathological analysis over a 3-month period
from February 2016 to May 2016.
As clinical records were not accessed, for the purpose
of this study CD was defined as:
I. either histological Marsh grades IIIa, IIIb or IIIc
(as defined by the Modified Marsh classification);
II. Marsh grades I or II or a report of increased intrae-
pithelial lymphocytosis in conjunction with a positive
serology result (anti-tTG antibody positive).
These definitions are based on the algorithm for the
diagnosis of CD laid out in the BSG guidelines.6 In our
institution, an IgA-tTG antibody level of 10U/mL is
regarded as definitely positive. Values of exactly 10U/
mL or just under 10U/mL are reported as either weakly
positive or equivocal—we have regarded these as nega-
tive results for the purpose of our study.
The study was registered with and approved by the
trust audit department, which did not deem local
research and development approval necessary due to
the study being purely an audit.
Exclusion criteria
Patients with known CD, having duodenal biopsies for
follow-up, were excluded. We also excluded records
where the number of biopsy specimens was not specified
(described as ‘several’ or ‘multiple’). For patients having
more than one endoscopy examination with duodenal
biopsies during one study period, we only considered
the first endoscopy. Duodenal bulb specimens (when
taken and specified in the histopathology report) were
included in the total count of number of duodenal spe-
cimens submitted.
Statistical analysis
The χ2 test was used to compare categorical variables
and the independent t-test to compare means of numer-
ical variables between the audit and reaudit groups. We
also used the χ2 test to assess the impact of compliance
to BSG guidelines on the proportion of patients diag-
nosed with CD (as per criteria defined above). We used
a generalised estimating equation (GEE) to identify
factors predicting adherence to guidance, while adjust-
ing for clustering by endoscopist. All p values are
2-sided. The IBM SPSS (V.24) software was used for all
statistical analyses.
RESULTS
A total of 973 endoscopies with duodenal biopsies were
performed from August 2014 to May 2015. Of these, 924
endoscopies were included in the study after applying
exclusion criteria. The respective figures for the reaudit
from February 2016 to May 2016 were 290 and 278.
Table 1 shows the characteristics of patients included in
the study. There were no significant differences between
groups in terms of patient demographics and indication
for biopsy. These 1263 endoscopies with duodenal biop-
sies performed across the two study periods (before
applying exclusion criteria) represent 27.5% of the total
number of upper gastrointestinal endoscopies per-
formed in our institution.
In the first part of the study, ≥4 biopsy specimens were
submitted for histopathological analysis in 21.9% of
cases (n=219). This increased to 60.8% (n=169) in the
reaudit following implementation of interventional mea-
sures (p<0.001). Even when ‘suspected coeliac disease/
malabsorption’ was the indication for biopsy, 39.2%
(n=47) of patients had ≥4 biopsies taken in the first
study period, but the corresponding figure was 60.0%
(n=18) in the reaudit (p=0.039). The modal number
of specimens submitted also changed from 3 to 4
(figure 1A,B).
Thirty-two patients were found to have CD in the first
cohort and 21 in the second (3.5% vs 7.6%, p=0.004). In
both groups of study, before and after intervention, the
diagnostic yield of CD when ≥4 biopsies were taken was
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higher than when <4 biopsies were taken. The diagnos-
tic rate of CD in the audit group was 2.0% (14 patients
out of 705) when <4 biopsies were taken and 8.2% (18
out of 219 patients) when >4 biopsies were taken
(p<0.001). The respective figures were 3.7% increasing
to 10.1% with ≥4 biopsies in the reaudit group
(p=0.049). The results from both parts of the study are
summarised in table 2.
A total of 42 different clinicians performed endosco-
pies with duodenal biopsies in the 1202 patients (audit
and reaudit groups combined). Eighteen of these clini-
cians performed at least 10 endoscopies, with the
remaining 24 performing fewer than 10 endoscopies
over the study periods considered. Between these 18
clinicians, a total of 1133 endoscopies were performed
(ie, 94% of the overall number of endoscopies per-
formed). Their overall compliance with guidelines
varied from 12% to 67% (SD 11.9%).
We therefore identified factors predicting overall
adherence to BSG guidelines (ie, submission of ≥4
biopsy specimens), while adjusting for clustering by clin-
ician, using GEE. The following parameters were
assessed as predictors of taking ≥4 biopsies: study group
(audit vs reaudit), age, sex, indication for biopsy and ser-
ology test result (positive or negative).
The reaudit group was associated with a significantly
increased odds of taking four or more biopsies com-
pared with the audit group (OR 5.3; 95% CI 3.8 to 7.5;
p<0.001). Suspected CD as an indication for biopsy also
had a higher odds of adhering to guidance (OR 2.45;
95% CI 1.01 to 6.17; p <0.05), while the lack of a positive
anti-tTG antibody result was associated with decreased
odds of compliance (OR 0.39; 95% CI 0.21 to 0.73;
p=0.003). The remaining factors considered did not
reach statistical significance.
DISCUSSION
Only a quarter of upper gastrointestinal endoscopies
performed in our institution result in duodenal biopsies,
which reinforces the fact that, when taken, the main aim
probably remains to diagnose or exclude CD. The
results of our initial audit thus demonstrate poor adher-
ence to established national recommendations in





Number Per cent Number Per cent p Value
Total number of endoscopies 973 290 -
Number included in study 924 – 278 –
Sex 0.705
Males 374 40.5 109 39.2
Females 550 59.5 169 60.8
Age (years)
Mean 59.2 59.7 0.692
Range 15.6–91.6 19.6–95.6
Indication 0.512
Anaemia 469 50.8 155 55.8
Suspected coeliac/malabsorption 120 13.0 30 10.8
Epigastric pain/dyspepsia 108 11.7 30 10.8
Weight loss 97 10.5 32 11.5
Diarrhoea 81 8.8 16 5.8
Reflux 22 2.4 5 1.8
Others 27 2.9 10 3.6
Serology test
Performed 465 50.3 126 45.3 0.144
Positive 37 4.0 18 6.5 0.084
Figure 1 Bar charts of number
of duodenal biopsies submitted
for histopathological analysis for
patients having an endoscopy
and duodenal biopsies between
(A) August 2014 and May 2015
and (B) February 2016 and May
2016.
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patients with no known diagnosis of CD, in whom this
diagnosis is being considered at endoscopy. This
remained suboptimal even when the clinical indication
for biopsies was ‘suspected coeliac disease’. Although
compliance only reached 60.8% in the reaudit, we have
been able to demonstrate that simple interventional
measures to raise awareness among endoscopists can be
successful in significantly improving compliance to guid-
ance. Potential barriers to adherence, as previously sug-
gested in the literature7 include lack of awareness
among clinicians of these guidelines and the extra time
required to take a larger number of samples due to mul-
tiple passes of the biopsy forceps.
Of the 18 endoscopists who performed the majority of
endoscopies during our study periods, only nine were
present at the Endoscopy User Group meeting
(November 2015) where we presented the results of our
audit and encouraged endoscopists to comply with guide-
lines. Furthermore, a number of clinicians performing
endoscopies in our trust are nor regular trust clinicians,
but rather are from external agencies. Thus, reasons for
failing to reach a higher rate of compliance in our postin-
tervention group may include the fact that the recommen-
dations from our initial study were not taken up by all
clinicians involved, and potentially our message did not
get across to everyone. The next stage of our study
involves a more targeted training approach, to also
include endoscopy nurses who are in a position to request
clinicians to take an adequate number of biopsies. A
formal assessment of individual clinicians’ perceptions
through questionnaires may further clarify barriers to
compliance, and potentially help us to improve it further.
The diagnostic rate of CD doubled following imple-
mentation of changes (7.6% in the reaudit vs 3.5% in the
audit). There were no statistically significant differences
between the audit and reaudit groups in terms of base-
line characteristics, hence why we postulate that the
higher probability of diagnosing CD in the reaudit group
is likely attributable to the higher proportion of patients
having ≥4 biopsies taken. In fact, within each group there
was a significant increase in the probability of a CD diag-
nosis when patients with <4 biopsy specimens were com-
pared with those with ≥4 specimens. Lebowhl et al7 also
reported a doubling of the diagnostic rate of CD when
four or more specimens are submitted for histology.
This raises the question of whether new diagnoses of
CD are being missed due to inadequate number of biop-
sies submitted. CD is believed to be largely underdiag-
nosed.9 A number of reasons for this have been
suggested in the literature including the patchy nature
of mucosal changes in CD, yield of biopsy samples that
are inadequate for histological analysis and variability in
histopathology reporting.10–12 Our results and those of
similar studies7 8 strongly favour the submission of an
adequate number of duodenal biopsies for histopatho-
logical analysis when a diagnosis of CD is considered.
The GEE analysis confirmed that while adjusting for
clustering by endoscopists, the odds of compliance to
guidelines still significantly increased in our reaudit
cohort. We found that a positive serology result and ‘sus-
pected coeliac disease’ as the principal indication for
biopsy to be independent predictors of the likelihood of
adhering to guidelines. In their study with a larger
sample size, Lebowhl et al7 also found increasing age to
be associated with decreased odds of submitting for
biopsy specimens.
Limitations
Our study was retrospective and performed using elec-
tronic records. With the lack of information regarding
clinical CD diagnosis, we formulated definitions of CD
based on histology and serology. We did not have com-
plete data on gross endoscopic findings, which are
inconsistently documented by endoscopists; these would
be best collected in a prospective design. Our reaudit
sample size is also relatively small, and our study limited
to a single centre. We have not quantified the exact
effect that our intervention has had on improving com-
pliance. However, all other factors have remained con-
stant across the two periods of study—see table 1—
therefore allowing us to conclude that our intervention
at least partly explains the improvement. We do aim to
carry out more focused training and qualitatively
measure its effect on clinicians’ practice before carrying
out a further reaudit.
CONCLUSION
Despite these limitations, our results are in line with pre-
vious studies. Our study has reiterated the fact that
Table 2 Differences between audit and reaudit groups in terms of number of biopsy specimens submitted for
histopathological analysis and diagnostic rate of coeliac disease
Audit (Aug 2014–May 2015)
Reaudit (Feb 2016–May
2016) p Value
Number Per cent Number Per cent
Number of biopsy specimens <0.001
<4 705 76.3 109 39.2
≥4 219 23.7 169 60.8
Mean 2.86 − 3.56 − <0.001
Coeliac disease 32 3.5 21 7.6 0.004
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adherence to BSG recommendations on the number of
duodenal biopsies taken at endoscopy when CD is sus-
pected does improve the diagnostic yield of CD. Simple
measures to increase awareness of this issue can improve
local compliance, with a potential improved detection of
CD. We also highlight the fact that despite the existence
of the BSG guidelines, overall compliance remains quite
poor at our centre, which may affect the diagnosis of
CD. Our results should prompt other centres to assess
their practice.
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